Alterome Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alterome.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1
Recruiting
- Conditions
- CancerCRC (Colorectal Cancer)PDAC - Pancreatic Ductal AdenocarcinomaAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Alterome Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT06835569
- Locations
- 🇺🇸
Research Site, Fairfax, Virginia, United States
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Alterome Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- 2024-515391-12-00
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
🇺🇸Research Site #2, San Antonio, Texas, United States
News
No news found